Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.

Bousquet J, Bachert C, Bernstein J, Canonica GW, Carr W, Dahl R, Demoly P, Devillier P, Hellings P, Fokkens W, Klimek L, Lieberman P, Meltzer E, Price D, Ryan D, Wahn U

Open source

DOI: 10.1517/14656566.2015.1020789
Published: 2015 Apr
Container: Expert opinion on pharmacotherapy
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1517/14656566.2015.1020789,
  title = {Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.},
  author = {Bousquet J and Bachert C and Bernstein J and Canonica GW and Carr W and Dahl R and Demoly P and Devillier P and Hellings P and Fokkens W and Klimek L and Lieberman P and Meltzer E and Price D and Ryan D and Wahn U},
  year = {2015},
  journal = {Expert opinion on pharmacotherapy},
  doi = {10.1517/14656566.2015.1020789},
  url = {https://doi.org/10.1517/14656566.2015.1020789}
}

RIS

TY  - JOUR
TI  - Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
AU  - Bousquet J
AU  - Bachert C
AU  - Bernstein J
AU  - Canonica GW
AU  - Carr W
AU  - Dahl R
AU  - Demoly P
AU  - Devillier P
AU  - Hellings P
AU  - Fokkens W
AU  - Klimek L
AU  - Lieberman P
AU  - Meltzer E
AU  - Price D
AU  - Ryan D
AU  - Wahn U
PY  - 2015
JO  - Expert opinion on pharmacotherapy
DO  - 10.1517/14656566.2015.1020789
UR  - https://doi.org/10.1517/14656566.2015.1020789
ER  -

APA

J, B., C, B., J, B., GW, C., W, C., R, D., P, D., P, D., P, H., W, F., L, K., P, L., E, M., D, P., D, R., & U, W. (2015). Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.. Expert opinion on pharmacotherapy. https://doi.org/10.1517/14656566.2015.1020789

Source records

pubmed · retrieved 2026-09-25T18:57:44.113Z
europe-pmc · retrieved 2026-09-25T18:57:44.094Z
hal · retrieved 2026-09-25T18:57:44.135Z